Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Crosses Above 200-Day Moving Average – Time to Sell?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $85.18 and traded as high as $85.92. Dianthus Therapeutics shares last traded at $85.81, with a volume of 1,679,417 shares changing hands.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of research reports. JPMorgan Chase & Co. began coverage on Dianthus Therapeutics in a report on Friday, September 11th. They issued an “overweight” rating and a $135.00 price target on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and set a $158.00 price target on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Finally, Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $128.54.

Dianthus Therapeutics Price Performance

The business’s 50-day moving average price is $91.11 and its 200 day moving average price is $85.18. The firm has a market capitalization of $4.70 billion, a price-to-earnings ratio of -20.68 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.81 earnings per share for the current year.

Insider Activity

In other Dianthus Therapeutics news, CAO Edward Carr sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the sale, the chief accounting officer owned 20,000 shares in the company, valued at approximately $2,027,600. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $425,640. The trade was a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 242,429 shares of company stock valued at $26,118,913 over the last quarter. 3.02% of the stock is owned by company insiders.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNTH. BlackRock Inc. acquired a new stake in Dianthus Therapeutics during the second quarter valued at $401,990,000. Wellington Management Group LLP boosted its position in shares of Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after acquiring an additional 634,099 shares during the period. Jennison Associates LLC acquired a new position in Dianthus Therapeutics in the 1st quarter valued at approximately $40,713,000. Assenagon Asset Management S.A. boosted its position in shares of Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after acquiring an additional 451,597 shares in the last quarter. Finally, Spruce Street Capital LP bought a new stake in Dianthus Therapeutics in the second quarter valued at $34,587,464. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.